Julia Kret

Julia Kret

Auto-generated profile, based on publicly available information

Julia Kret

Wroclaw Medical University, wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
ZRZuzanna Rafałowska
Zuzanna Rafałowska
SRStanisław Rutz
Stanisław Rutz
AWAnna Wojtala
Anna Wojtala
JKJulia Kret
Julia Kret
AWAleksandra Wyrostkiewicz
Aleksandra Wyrostkiewicz
MBMagda Buśko
Magda Buśko
Introduction. The common cold is one of the most prevalent acute respiratory infections worldwide and represents a significant public health and socioeconomic burden. Due to the lack of curative antiviral therapies and the limited effectiveness of conventional symptomatic treatment, there is growing interest in dietary supplements and herbal preparations that may prevent infection, shorten disease duration, or alleviate symptom severity. Materials and Methods. A structured literature search was conducted using PubMed and Google Scholar databases. Priority was given to systematic reviews, meta-analyses, and randomized controlled trials evaluating the effects of Vitamin D, Vitamin C, cloves (Syzygium aromaticum), zinc, Black elderberry (Sambucus nigra), ginseng (Panax spp.), echinacea (Echinacea spp.), Pelargonium sidoides, and Black seed (Nigella sativa) on the prevention and treatment of the common cold. Studies were assessed according to evidence-based medicine principles, with emphasis on clinical outcomes such as incidence, duration, and severity of symptoms. Results: The reviewed evidence indicates that zinc lozenges and standardized echinacea preparations provide the most consistent benefits in reducing the duration and severity of common cold symptoms when administered early. Among the analyzed interventions, echinacea was the only one that demonstrated a reproducible preventive effect against the development of the common cold. Black elderberry and Pelargonium sidoides were associated with clinically meaningful reductions in symptom severity and illness duration, although evidence for their preventive efficacy remains limited. Vitamin C and Vitamin D showed modest benefits primarily in specific populations, such as individuals exposed to intense physical stress or those with Vitamin D deficiency. Evidence regarding ginseng was inconsistent, while cloves and Nigella sativa lacked robust clinical trials specifically addressing the common cold despite encouraging preliminary findings. Conclusions. Several dietary supplements and herbal preparations may offer therapeutic benefits in the management of the common cold; however, their effectiveness varies considerably depending on formulation, dosage, timing of administration, and population studied. Echinacea emerges as the most promising agent for prevention, while zinc, elderberry, and Pelargonium sidoides appear most relevant for symptom reduction and illness shortening. Further high-quality, standardized randomized controlled trials are required to clarify preventive efficacy and establish clear clinical recommendations.

30 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JKJulia Kret
Julia Kret
AZAdrianna Zabiegałowska
Adrianna Zabiegałowska
MSMichał Szpunar
Michał Szpunar
LZLilianna Zielińska
Lilianna Zielińska
JGJan Gdula
Jan Gdula
MBMagda Buśko
Magda Buśko
Introduction. Atopic Dermatitis (AD) is a complex, chronic, profoundly pruritic inflammatory dermatosis characterized by compromised epidermal barrier and relapsing-remitting course. While systemic therapies and targeted immunomodulators have revolutionized the management of moderate-to-severe disease presentations, the foundational pillar of AD management across all spectrums of severity remains the proactive restoration and maintenance of the stratum corneum. This comprehensive review summarizes clinical evidence regarding the pathophysiology of the atopic skin barrier, detailing the genetic implications of FLG loss-of-function mutations, the specific biochemical depletion of intercellular lipids (particularly ceramides), and the resultant microbiome dysbiosis driven by Staphylococcus aureus colonization. Materials and Methods. A systematic, rigorous search of peer-reviewed literature was conducted to synthesize current, evidence-based practices regarding skin barrier optimization in Atopic Dermatitis. A comprehensive literature search was executed across major medical and scientific databases, primarily utilizing PubMed/MEDLINE, Google Scholar, the Cochrane Central Register of Controlled Trials and Embase. Data were extracted focusing on the biochemical properties of the skin barrier, the comparative efficacy of various emollient formulations, and the specific clinical outcomes related to proactive versus reactive treatment modalities. The extracted data were analyzed and structured to provide a cohesive guide that translates complex dermatological science into actionable clinical management strategies. Results: The literature demonstrates that skin barrier dysfunction in Atopic Dermatitis is driven by FLG loss-of-function mutations, a distinct depletion of intercellular lipids (predominantly ceramides), and secondary Staphylococcus aureus microbiome dysbiosis. To counteract these defects, the evidence supports a foundational, multi-pronged barrier management approach. Successful strategies include evidence-based therapeutic bathing protocols, the precise application of targeted emollient classes, and the utilization of the "soak and smear" technique to lock in moisture. Furthermore, integrating these interventions with adjunctive pharmacotherapy, strict trigger avoidance, and comprehensive patient-centered education significantly enhances overall treatment efficacy and barrier integrity. Conclusions: Proactive, continuous maintenance of the stratum corneum remains the indispensable foundation of AD management, regardless of disease severity. Rather than relying on reactive treatments for acute flare-ups, clinicians must shift toward a holistic paradigm of continuous barrier optimization. This proactive strategy is essential not only for managing structural and microbial skin defects but also for potentially arresting the atopic march and alleviating the profound psychosocial burden carried by AD patients.

21 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JPJagoda Pałubska
Jagoda Pałubska
OMOliwer Muller
Oliwer Muller
ZRZuzanna Rafałowska
Zuzanna Rafałowska
SRStanisław Rutz
Stanisław Rutz
AWAnna Wojtala
Anna Wojtala
MBMagda Buśko
Magda Buśko
Artificial intelligence (AI) is increasingly discussed as a transformative force in medicine, yet its practical value depends less on algorithmic promise alone than on whether tools can be integrated safely, intelligibly, and sustainably into clinical care. This review examines how free full-text PubMed literature describes the real-world implementation of AI in healthcare and identifies the technical, organizational, ethical, and social conditions that shape adoption. A structured narrative review was conducted using a targeted PubMed search with a free full-text filter, supplemented by focused searches on explainability, governance, workflow, bias, and implementation in clinical settings. The final core synthesis drew on 21 peer-reviewed articles published between 2019 and 2025, including reviews, qualitative studies, survey studies, consensus guidance, and quality-improvement evaluations. Across the literature, implementation emerged as a sociotechnical challenge rather than a purely technical one. Recurrent themes included the gap between proof-of-concept performance and routine use, the need for practical explainability, risks related to bias and patient safety, workflow and workforce adaptation, and the importance of lifecycle governance. Real-world studies suggest that AI can reduce documentation burden, improve structured data capture, and support triage or decision support, but adoption remains uneven and often limited by poor integration, uncertain accountability, insufficient training, and weak post-deployment monitoring. The review concludes that clinical AI should be evaluated not only by accuracy but also by its fit with human work, organizational routines, fairness, and governance.

5 May 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
AWAnna Wojtala
Anna Wojtala
ZRZuzanna Rafałowska
Zuzanna Rafałowska
SRStanisław Rutz
Stanisław Rutz
JKJulia Kret
Julia Kret
AWAleksandra Wyrostkiewicz
Aleksandra Wyrostkiewicz
MBMagda Buśko
Magda Buśko
Introduction. Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age and is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. The syndrome is frequently associated with metabolic disturbances such as insulin resistance, obesity, dyslipidemia, and chronic inflammation, which increase the risk of long-term cardiometabolic complications. Due to its complex and multifactorial pathophysiology, effective management of PCOS requires a comprehensive and individualized therapeutic approach. Materials and methods. Relevant literature was identified through a structured search of PubMed and Google Scholar databases. The search included terms such as “PCOS treatment,” “PCOS pharmacological treatment,” and “PCOS alternative treatment,” followed by more specific phrases related to diet, exercise, oral contraceptives, antiandrogens, metformin, GLP-1 receptor agonists, nutritional supplements, herbal medicine, and surgical treatment. The analysis primarily included systematic reviews, meta-analyses, and randomized controlled trials in accordance with Evidence-Based Medicine (EBM) principles. Results. The reviewed evidence indicates that lifestyle modification, including weight reduction, dietary changes, and regular physical activity, remains the cornerstone of PCOS management and can significantly improve metabolic and reproductive outcomes. Pharmacological therapies such as combined oral contraceptive pills, antiandrogens, metformin, and GLP-1 receptor agonists effectively address menstrual irregularities, hyperandrogenism, and insulin resistance. In addition, nutritional supplementation and herbal medicine may provide supportive benefits by improving insulin sensitivity, reducing inflammation, and regulating hormonal balance. For patients with infertility who do not respond to pharmacological ovulation induction, laparoscopic ovarian drilling may be considered as a second-line treatment. Conclusions. PCOS management requires a multidisciplinary and individualized approach combining lifestyle interventions, pharmacological therapy, and complementary treatments. Further high-quality clinical studies are needed to better evaluate emerging therapies and optimize long-term treatment strategies for women with PCOS.

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
OMOliwer Műller
Oliwer Műller
JPJagoda Pałubska
Jagoda Pałubska
ZRZuzanna Rafałowska
Zuzanna Rafałowska
SRStanisław Rutz
Stanisław Rutz
AWAnna Wojtala
Anna Wojtala
MBMagda Buśko
Magda Buśko
Artificial intelligence is increasingly used in medical imaging, clinical decision support, and digital triage. However, technical performance alone does not determine whether such tools will be accepted in practice. Their implementation also depends on whether patients perceive them as understandable, safe, fair, and compatible with person-centred care. This review examines the main factors that shape patient trust in AI-assisted diagnosis and triage and discusses the social and ethical conditions that support responsible adoption. A structured narrative review design was used to synthesize recent literature on patient attitudes toward clinical AI, with particular attention to radiology, diagnostic support, communication, explainability, accountability, and emerging triage applications. The literature shows a consistent pattern of conditional acceptance. Patients are often willing to accept AI when it is used as a support tool under clinician supervision, but they are much more hesitant when AI is framed as replacing doctors in final decision-making. Trust is influenced not only by explainability, but also by validation, data quality, fairness, privacy, communication, and visible human accountability. Patients repeatedly express the wish to be informed when AI is involved in their care and to retain access to a clinician who can interpret results, answer questions, and assume responsibility. The review argues that trust in medical AI should be understood as calibrated confidence rather than simple approval or rejection. From a social-science perspective, AI in diagnosis and triage is a sociotechnical arrangement whose legitimacy depends on governance, workflow design, and the continued protection of the doctor-patient relationship.

23 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
PBPaulina Bigda
Paulina Bigda
ZRZuzanna Rafałowska
Zuzanna Rafałowska
SRStanisław Rutz
Stanisław Rutz
AWAnna Wojtala
Anna Wojtala
JKJulia Kret
Julia Kret
OMOliwer Muller
Oliwer Muller
Introduction. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally developed as antidiabetic agents exploiting the incretin effect to achieve glucose-dependent insulin secretion. Over the past decade, evidence from large-scale cardiovascular outcome trials (CVOTs), mechanistic studies, and emerging clinical investigations has demonstrated that the therapeutic potential of this drug class extends well beyond glycaemic control. GLP-1 receptors are expressed in the heart, vasculature, kidneys, brain, liver, lungs, and immune cells, providing the biological substrate for diverse extra-metabolic effects observed in both preclinical models and clinical cohorts. Methodology. This narrative review was conducted through a systematic search of PubMed, MEDLINE, and the Cochrane Library using MeSH terms and free-text keywords related to GLP-1 RAs and their extra-metabolic effects. Publications up to early 2026 were considered, including randomised controlled trials, CVOTs, systematic reviews, meta-analyses, and mechanistic preclinical studies. Eligibility was based on methodological rigour, sample size, and clinical relevance to four main domains: cardiovascular, renal, neurological, and anti-inflammatory effects. Results. GLP-1 RAs demonstrated a 13–14% reduction in major adverse cardiovascular events (MACE) across CVOTs, with semaglutide reducing MACE by 20% in patients with obesity but without diabetes (SELECT trial). In the renal domain, the FLOW trial showed a 24% reduction in the composite renal endpoint (HR 0.76; 95% CI: 0.66–0.88; p < 0.001) with semaglutide in patients with diabetic kidney disease. In the neurological domain, preclinical evidence strongly supports neuroprotection in Alzheimer's and Parkinson's disease, with initial clinical trials showing improvement in motor function in Parkinson's patients treated with exenatide or lixisenatide and prevention of cerebral metabolic decline in Alzheimer's disease with liraglutide. Anti-inflammatory properties — demonstrated across hepatic (NASH resolution in up to 59% with semaglutide), pulmonary, dermatological, and systemic contexts — further broaden the therapeutic scope. Emerging data also suggest potential roles in obstructive sleep apnoea, substance use disorders, and knee osteoarthritis. Conclusions. GLP-1 RAs constitute a versatile class of pleiotropic, disease-modifying agents with organ-protective properties extending far beyond glycaemic management. The advent of dual GIP/GLP-1 agonists (tirzepatide) and investigational triple agonists further expands this landscape. Significant gaps remain regarding long-term neurological outcomes, optimal patient selection, and the relative contributions of direct receptor-mediated versus weight-loss-dependent effects, necessitating dedicated mechanism-focused trials and biomarker-guided patient stratification.